Literature DB >> 28411367

Serum 25(OH)D concentration, common variants of the VDR gene and lung cancer occurrence.

Tomasz Gromowski1, Paulina Gapska1, Rodney J Scott2, Krzysztof Kąklewski1, Wojciech Marciniak3, Katarzyna Durda1, Marcin Lener1, Bohdan Górski1, Cezary Cybulski1, Grzegorz Sukiennicki1, Katarzyna Kaczmarek1, Katarzyna Jaworska-Bieniek1, Katarzyna Paszkowska-Szczur1, Piotr Waloszczyk4, Jan Lubiński1,3, Tadeusz Dębniak1.   

Abstract

The first aim of our study was to examine the association between common variants in VDR [rs2228570 (FokI), rs1544410 (BsmI), rs7975232 (ApaI), rs731236 (TaqI) and rs11568820 (Cdx2)] and lung cancer risk in the Polish population. Genotyping and statistical analysis which included Chi-square test with Yates correction and haplotype frequency analysis were performed on a series of 840 consecutively collected lung cancer patients and 920 healthy controls. The second aim was to evaluate the link between serum 25(OH)D concentration and the number of lung cancers in a subgroup of 200 patients. A separate control group that consisted of 400 matched (by age, sex, smoking habits and the season of blood collection) healthy individuals was used to avoid posterior adjustment on the matched variables. Statistical analysis with the use of Chi-square test with Yates was performed. We found no statistically significant difference in the distribution of the allels of studied VDR variants among cases and controls. A statistically significant over-representation of VDR haplotypes: rs731236_A + rs1544410_T [odds ratio (OR) = 2.43, 95% confidence interval (CI) = 1.11-5.32, p < 0.001], rs731236_G + rs1544410_T (OR = 1.54, 95% CI = 1.31-1.81, p < 0.001) and rs731236_G + rs1544410_C (OR = 0.04, 95% CI = 0.03-0.07, p < 0.001) was detected. We found a tendency toward an increased number of lung cancers among individuals with low serum levels of 25(OH)D. To answer the question, whether VDR can be regarded as lung cancer susceptibility gene and low 25(OH)D serum levels is associated with lung cancer occurrences, additional, multicenter study needs to be performed.
© 2017 UICC.

Entities:  

Keywords:  25(OH)D; VDR; lung cancer; vitamin D

Mesh:

Substances:

Year:  2017        PMID: 28411367     DOI: 10.1002/ijc.30740

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Vitamin D Receptor Deletion Leads to the Destruction of Tight and Adherens Junctions in Lungs.

Authors:  Honglei Chen; Rong Lu; Yong-Guo Zhang; Jun Sun
Journal:  Tissue Barriers       Date:  2018-11-08

2.  Associations of VDR gene polymorphisms with risk of coal workers' pneumoconiosis in Chinese Han population.

Authors:  Xi Yang; Meiting Qin; Shanshan Cui; Qi Zhang
Journal:  Toxicol Res (Camb)       Date:  2020-06-17       Impact factor: 3.524

Review 3.  Associations of the risk of lung cancer with serum 25-hydroxyvitamin D level and dietary vitamin D intake: A dose-response PRISMA meta-analysis.

Authors:  Hu Wei; Hu Jing; Qian Wei; Guo Wei; Zhou Heng
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

4.  Genetic polymorphisms may influence the vertical growth rate of melanoma.

Authors:  Mariusz Sikora; Lidia Rudnicka; Barbara Borkowska; Agnieszka Kardynał; Monika Słowińska; Adriana Rakowska; Olga Warszawik-Hendzel; Anna Wiergowska; Iwona Ługowska; Piotr Rutkowski; Tadeusz Dębniak; Jan Lubiński; Małgorzata Olszewska
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

5.  Epidemiological Study of Lung Cancer and Clinical Medication in England from 2001 to 2019.

Authors:  Baokun Zhang; Ying Yang
Journal:  J Healthc Eng       Date:  2022-03-23       Impact factor: 2.682

6.  Assessment of Specific Tumoral Markers, Inflammatory Status, and Vitamin D Metabolism before and after the First Chemotherapy Cycle in Patients with Lung Cancer.

Authors:  Andreea Crintea; Cristina Drugan; Anne-Marie Constantin; Iulia Lupan; Zsolt Fekete; Ciprian Nicolae Silaghi; Alexandra Mărioara Crăciun
Journal:  Biology (Basel)       Date:  2022-07-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.